Apr 05, 2013 2:01am EDT AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
Jan 03, 2013 7:30am EST Rigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation
Dec 13, 2012 7:30am EST AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
Sep 05, 2012 7:30am EDT Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
